评论模板（争议，原创图表，JTO）

支持：
Zhou F, Zhou C. Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors. J Thorac Oncol. 2021 Oct;16(10):1622-1626. doi: 10.1016/j.jtho.2021.07.011. PMID: 34561035.


配有原创图表1




反对：
Zhang JT, Wu YL. Combination Chemotherapy Alone Should Be Used in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors. J Thorac Oncol. 2021 Oct;16(10):1627-1631. doi: 10.1016/j.jtho.2021.06.033. PMID: 34561036.





配有原创图表2


配有原创图表3